Date: 2015-01-05
Type of information: Nomination
Compound:
Company: Catalyst Pharmaceutical Partners (USA - FL)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 5, 2015, Catalyst Pharmaceutical Partners announced that David D. Muth, currently Executive Vice President, Corporate Development of Catalyst, has been promoted to the newly created position of Executive Vice President, Chief Commercial Officer, effective January 1, 2015. Mr. Muth will continue to report to Patrick J. McEnany, Chairman and Chief Executive Officer of Catalyst. In his expanded role, Mr. Muth will be responsible for all of Catalyst\'s commercial operations and corporate development activities. In that role, he will work closely with the other members of the Catalyst team in developing and executing the Company\'s strategic plan, including the anticipated commercial launch of Firdapse™. Mr. Muth has over 35 years of business experience in the biotechnology and pharmaceutical industries. He most recently served, from 2010 to 2014, as the President and CEO of Croma Pharmaceuticals Inc., where he established North American operations, gained approval of and successfully launched 10 ocular surgical products, while building a Canadian Ophthalmology sales organization. Prior to joining Croma, from 2008 to 2010, David was the Global Head of Business Development for Bausch + Lomb\'s (B+L) Pharmaceutical Group, where he negotiated numerous transactions including company/products acquisitions and in-licensed a portfolio of programs. Prior to B+L, he served as the Executive Vice President and Chief Business Officer for Avalon Pharmaceuticals, President and CEO of Osmotica Pharmaceutical Corporation, President and COO of Cengent Therapeutics and Senior Vice President of Business Operations for Nabi Biopharmaceuticals Inc. At Nabi, he established a hematological/oncology commercial organization and launched four products, two of which were Orphan Drugs. Prior to Nabi, Mr. Muth spent 17 years with Johnson & Johnson (J&J) in a variety of senior management roles spanning all commercial functions including marketing research, sales, product management, new product development, and corporate development. Mr. Muth received a B.S. in accounting from Villanova University, an M.B.A. in Finance from Pace University and an M.B.A. in Pharmaceutical Marketing (2nd concentration) from Farleigh Dickinson University.
Financial terms:
Latest news:
